Carlos A Dujovne

Summary

Affiliation: Radiant Research
Country: USA

Publications

  1. ncbi request reprint Treatment of Familial Hypercholesterolemia and Other Genetic Dyslipidemias
    Carlos A Dujovne
    Kansas Foundation for Clinical Pharmacology and Therapeutics, 12200 W 106th Street, Suite 330, Overland Park, KS 66215, USA E mail
    Curr Treat Options Cardiovasc Med 6:269-278. 2004
  2. ncbi request reprint Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group
    C A Dujovne
    Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, Overland Park 66215, USA
    Mayo Clin Proc 75:1124-32. 2000
  3. ncbi request reprint Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
    C A Dujovne
    Lipid, Arteriosclerosis and Metabolic Clinic, University of Kansas Medical Center, Kansas City, USA
    Am J Cardiol 85:350-3. 2000
  4. ncbi request reprint Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
    Carlos A Dujovne
    Kansas Foundation for Clinical Pharmacology, Radiant Research Kansas City, 12200 W 106th Street, Suite 330, Overland Park, KS 66215, USA
    Am J Cardiol 90:1092-7. 2002
  5. ncbi request reprint Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 92:538-43. 2003
  6. ncbi request reprint Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis"
    Carlos A Dujovne
    Am J Cardiol 89:1411-3. 2002
  7. ncbi request reprint Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Jonathan Isaacsohn
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Clin Cardiol 26:18-24. 2003
  8. ncbi request reprint Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 91:667-72. 2003
  9. ncbi request reprint Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois 60610, USA
    Clin Cardiol 26:509-14. 2003

Detail Information

Publications9

  1. ncbi request reprint Treatment of Familial Hypercholesterolemia and Other Genetic Dyslipidemias
    Carlos A Dujovne
    Kansas Foundation for Clinical Pharmacology and Therapeutics, 12200 W 106th Street, Suite 330, Overland Park, KS 66215, USA E mail
    Curr Treat Options Cardiovasc Med 6:269-278. 2004
    ..Plasmapheresis, intestinal shunts, or liver transplantation are to be considered in that order as last resorts if the above fails to accomplish serum lipid level goals...
  2. ncbi request reprint Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1,030 hypercholesterolemic patients. The Cerivastatin Study Group
    C A Dujovne
    Kansas Foundation for Clinical Pharmacology, Radiant Research, Kansas City, Overland Park 66215, USA
    Mayo Clin Proc 75:1124-32. 2000
    ..To determine the relative efficacy and safety of cerivastatin and pravastatin in patients with type II hypercholesterolemia...
  3. ncbi request reprint Effect of atorvastatin on hemorheologic-hemostatic parameters and serum fibrinogen levels in hyperlipidemic patients
    C A Dujovne
    Lipid, Arteriosclerosis and Metabolic Clinic, University of Kansas Medical Center, Kansas City, USA
    Am J Cardiol 85:350-3. 2000
    ....
  4. ncbi request reprint Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia
    Carlos A Dujovne
    Kansas Foundation for Clinical Pharmacology, Radiant Research Kansas City, 12200 W 106th Street, Suite 330, Overland Park, KS 66215, USA
    Am J Cardiol 90:1092-7. 2002
    ..Ezetimibe 10 mg/day is well tolerated, reduces LDL cholesterol approximately 17%, and improves other key lipid parameters...
  5. ncbi request reprint Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 92:538-43. 2003
    ..At the higher doses, gemcabene significantly reduced LDL cholesterol levels in all patients with low HDL cholesterol...
  6. ncbi request reprint Side effects of statins: hepatitis versus "transaminitis"-myositis versus "CPKitis"
    Carlos A Dujovne
    Am J Cardiol 89:1411-3. 2002
  7. ncbi request reprint Effects of simvastatin, an HMG-CoA reductase inhibitor, in patients with hypertriglyceridemia
    Jonathan Isaacsohn
    Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, USA
    Clin Cardiol 26:18-24. 2003
    ....
  8. ncbi request reprint Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE])
    Harold E Bays
    Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky 40213, USA
    Am J Cardiol 91:667-72. 2003
    ....
  9. ncbi request reprint Differential effects of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I are consistent across hypercholesterolemic patient subgroups
    Michael H Davidson
    Chicago Center for Clinical Research, Chicago, Illinois 60610, USA
    Clin Cardiol 26:509-14. 2003
    ..In addition to lowering plasma levels of low-density lipoprotein cholesterol (LDL-C), statins also raise high-density lipoprotein cholesterol (HDL-C)...